<DOC>
	<DOC>NCT02895750</DOC>
	<brief_summary>There is limited data availability on effect of Metformin XR on 24-h plasma glucose, and there is no available data in chronic kidney disease (CKD). The planned study aims to provide data on glucose plasma level in relation to metformin plasma level in Diabetes Type II patients.</brief_summary>
	<brief_title>Efficacity and Safety of Metformin XR in CKD Stage 1 to 3</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Type 2 diabetes patients aged between 18 and 80 years requiring metformin (and any other antidiabetic treatment) Pregnancy and lactation Hyperlactatemia (&gt; 2.5 mmol/L) No creatinine levels available since 3 months Severe hepatic insufficiency No liver function parameters available Need of investigation with iodized contrast media Hypersensitivity to metformin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>diabetes type 2</keyword>
	<keyword>Metformin</keyword>
	<keyword>chronic kidney disease</keyword>
	<keyword>CKD</keyword>
</DOC>